multiple sclerosis

Sanofi’s Lemtrada MS Drug Effective in Extension Trial

Sanofi’s Lemtrada MS Drug Effective in Extension Trial

Bloomberg

Biogen’s MS Pill Gains 8 More Years of Patent Protection

Biogen’s MS Pill Gains 8 More Years of Patent Protection

Bloomberg

4 Key Drug Approvals Expected In The Next 30 Days

4 Key Drug Approvals Expected In The Next 30 Days

investors.com

Teva Enrolls Patients in MS Study - Analyst Blog

Teva Enrolls Patients in MS Study - Analyst Blog

NASDAQ

Teva to begin new Laquinimod Phase III trial

Teva to begin new Laquinimod Phase III trial

Globes, Israel

Coronado Biosciences: 2013 - Year Of The Worm

Coronado Biosciences: 2013 - Year Of The Worm

Seeking Alpha

A Strong Growth Opportunity In Multiple Sclerosis

A Strong Growth Opportunity In Multiple Sclerosis

Motley Fool

A Win-Win Multiple Sclerosis Deal?

A Win-Win Multiple Sclerosis Deal?

Motley Fool

Merck KGaA signs $225 million personalized MS drug deal

Merck KGaA signs $225 million personalized MS drug deal

Pharma Times, UK

Biogen pays Elan $3.25 billion to take over MS drug

Biogen pays Elan $3.25 billion to take over MS drug

Reuters